Q&A with Melissa Harris from Bristol-Myers Squibb: Expanding Hepatitis C Treatment to New Genotypes and Populations
Although there are now effective treatments for several genotypes of hepatitis C, certain patient groups continue to present challenges for the pharmaceutical and medical communities. Work is being done to overcome those challenges around the world.
Although there are now effective treatments for several genotypes of hepatitis C, certain patient groups continue to present challenges for the pharmaceutical and medical communities. Work is being done to overcome those challenges around the world.
Melissa Harris, Worldwide Medical Lead for Hepatitis C at Bristol-Myers Squibb, discussed some of the work the company is doing at the 2015 Liver Meeting in San Francisco. Harris said not only are there developments in the treatment of genotype 3 of the disease, but there has also been a push to help bring treatment to patients in China and other countries in the Pacific Rim.
